Bupivacaine Hydrochloride

PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the three months ended June 30, 2026. “We continue to make progress on the requirements for resubmission of our New Drug Application (NDA) for GTx-104,” said Prashant Kohli, Chief Executive Officer of Grace Therapeutics. “As previously disclosed, the U.S. Food and Drug Administration’s (FDA) Complete Response Letter (CRL) identified no clinical safety or efficacy deficiencies—the remaining items relate to chemistry, manufacturing and controls (CMC) and non-clinical data. We continue to address those items while advancing two manufacturing sites toward NDA resubmission. Our current contract manufacturer is remediating the FDA’s facility-level findings, while our second, U.S.-based contract manufacturer is advancing the technology transfer needed to begin the required 12-month stability program. NDA resubmission timing will reflect whichever manufacturing site reaches readiness first. The recent financing extends our expected cash runway through the end of calendar 2028, positioning us to execute on both manufacturing sites as we work toward NDA resubmission. We look forward to reporting our progress as we achieve these important milestones.” First Quarter 2027 and Recent Corporate Highlights Announced a $10 million private placement financing with new and existing institutional and accredited investors. The Company intends to use the net proceeds from the financing to support the manufacturing and regulatory work needed to advance GTx-104.Announced receipt of the FDA meeting minutes from a Type A Meeting held with the FDA to discuss the CRL issued on April 23, 2026. The minutes constitute the official record of the Type A meeting. As previously disclosed, the CRL did not identify any clinical safety or efficacy deficiencies and did not request additional clinical data. The items cited by the FDA relate to the current good manufacturing practice (cGMP) compliance status of the Company’s contract manufacturing organization — a facility-level matter, and not a GTx-104 product-specific quality finding — together with additional leachables data time points and excipient toxicology risk assessments. The Company intends to address each of the CRL items in its planned resubmission, including completing the required non-clinical studies.As part of its resubmission plan, the Company has initiated a dual-source manufacturing strategy for GTx-104 to mitigate potential remediation issues from the Company’s current contract manufacturer and provide flexibility, while continuing to address the remaining CMC and non-clinical items identified in the CRL. As such, a technology transfer to a second, U.S.-based contract manufacturer is already underway. The timing of NDA resubmission will reflect the manufacturing pathway that reaches readiness first: either (i) the U.S.-based facility, which would require completion of a full CMC package supported by 12 months of stability data following the technology transfer; or (ii) the Company’s current contract manufacturer, if it successfully remediates its FDA compliance issues and is able to support the NDA sooner. First Quarter 2027 Financial Results The Company reported a net loss of $15.8 million, or $0.91 loss per share for the three months ended June 30, 2026, compared to $3.4 million, or $0.21 loss per share, for the quarter ended June 30, 2025. The increase in net loss was primarily due to a $13.5 million impairment of IPR&D related to GTx-101 and GTx-102 as further described below. This increase was partially offset by a favorable $0.5 million difference in the change in fair value of derivative warrant liabilities and a $0.4 million decrease in general and administrative expenses. Cash used in operations was approximately $3.2 million. Consistent with the Company’s previously announced 2023 decision to deprioritize GTx-101 and GTx-102 in favor of GTx-104, and following reevaluation of strategic priorities during the first quarter of 2027, the Company recorded a full impairment of the remaining IPR&D carrying value associated with GTx-101 and GTx-102. The Company also evaluated the carrying value of its IPR&D related to GTx-104 following the receipt of the CRL. Based on the assessment, the Company determined that the fair value exceeds the carrying amount, and no impairment charge was required for the quarter ended June 30, 2026. Total research and development expenses for the three months ended June 30, 2026, were $0.7 million, compared to $1.0 million three months ended June 30, 2025. The decrease was primarily due to a $0.3 million decrease in research activities mainly due to the completion of our GTx-104 pivotal Phase 3 STRIVE-ON safety clinical trial and submission of our NDA to the FDA during the prior period, whereas the current period research activities were only focused on addressing certain items identified in the CRL from the FDA. General and administrative expenses were $1.7 million for the three months ended June 30, 2026, a decrease of $0.4 million from $2.1 million for the three months ended June 30, 2025. The decrease was primarily a result of a decrease in pre-commercial planning activities for GTx-104 offset in part by increased legal costs related to the Type A meeting with the FDA, and a decrease in stock-based compensation due to the issuance of new stock option awards for the three months ended June 30, 2025, with no such issuance occurring for the three months ended June 30, 2026. Cash Runway As of August 11, 2026, cash and cash equivalents were $22.2 million, The Company plans to use its current cash towards resolving the items cited in the CRL, working capital and other general corporate purposes. The Company believes its existing cash and cash equivalents will be sufficient to sustain planned operations, including the activities to address the items cited in the CRL, through the end of calendar 2028. About aneurysmal Subarachnoid Hemorrhage (aSAH) aSAH is bleeding over the surface of the brain in the subarachnoid space between the brain and the skull, which contains blood vessels that supply the brain. A primary cause of such bleeding is the rupture of an aneurysm in the brain. The result is aSAH, a relatively uncommon type of stroke that accounts for about 5% of all strokes and an estimated 42,500 U.S. hospital treated patients. About GTx-104 GTx-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for IV infusion in aSAH patients to address significant unmet medical needs. The unique nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. GTx-104 provides a convenient IV delivery of nimodipine in the Intensive Care Unit potentially eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Intravenous delivery of GTx-104 also has the potential to lower food effects, drug-to-drug interactions, and eliminate potential dosing errors. Further, GTx-104 has the potential to better manage hypotension in aSAH patients. GTx-104 has been administered in over 200 patients and healthy volunteers and was well tolerated with significantly lower inter- and intra-subject pharmacokinetic variability compared to nimodipine oral capsules. About Grace Therapeutics Grace Therapeutics, Inc. (Grace Therapeutics or the Company) is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Grace Therapeutics’ novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery. Grace Therapeutics’ lead clinical asset, GTx-104, is an IV infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. GTx-104 has been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States if certain conditions are met at NDA approval, and additional intellectual property protection with 52 granted and pending patents. For more information, please visit: www.gracetx.com. Forward-Looking Statements Statements in this press release that are not statements of historical or current fact constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and “forward-looking information” within the meaning of Canadian securities laws (collectively, “forward-looking statements”). Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Grace Therapeutics to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements containing the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “estimates,” “potential,” “should,” “may,” “will,” “plans,” “continue,” “targeted” or other similar expressions to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The forward-looking statements in this press release, including statements regarding the Company’s cash runway; future prospects of the Company’s GTx-104 drug candidate; the Company’s belief that the issues identified by the FDA in the CRL can be successfully addressed in the Company’s resubmission of the NDA for GTx-104; the Company’s planned approach to addressing the items cited in the CRL following its Type A meeting with the FDA and receipt of the official meeting minutes; the Company’s dual source manufacturing strategy, including remediation at its current contract manufacturer and technology transfer to a second, U.S.-based contract manufacturer; the timing and outcome of any FDA reinspection of the current contract manufacturer; the Company’s plans to complete the required non-clinical studies; and the Company’s plans to report progress against key milestones; GTx-104’s potential to bring enhanced treatment options to patients suffering from aSAH; the ability of GTx-104 to potentially eliminate the need for nasogastric tube administration in unconscious or dysphagic patients; the potential of GTx-104 to lower food effects, drug-to-drug interactions, and to eliminate potential dosing errors; the potential of GTx-104 to better manage hypotension in aSAH patients; and the Company’s intellectual property estate for GTx-104, are based upon Grace Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (i) the timing and success of any regulatory resubmission of the NDA for GTx-104; (ii) the timing of any FDA reinspection of the Company’s current contract manufacturer, and that facility’s compliance status, which are determined by the FDA and outside the Company’s control, and the FDA’s position that it will not approve the NDA while the facility remains in an unacceptable compliance status; (iii) the ability of a second, U.S.-based contract manufacturer to generate the required stability and analytical data and to complete a product-specific pre-approval inspection; (iv) the need to complete additional non-clinical studies; (v) the requirement that any resubmission comprehensively address all items cited in the CRL and the risk of review delay; (vi) the Company’s potential need for additional capital, which may not be available on acceptable terms; (vii) changes to regulatory pathways; (viii) the Company’s ability to protect its intellectual property for GTx-104; and (ix) legislative, regulatory, political and economic developments. The foregoing list of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in the “Special Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2026 filed with the Securities and Exchange Commission (SEC) and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, to be filed with the SEC and other documents that have been and will be filed by Grace Therapeutics from time to time with the SEC and Canadian securities regulators. All forward-looking statements contained in this press release speak only as of the date on which they were made. Grace Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by applicable securities laws. For more information, please contact: Grace Therapeutics Contact: Prashant Kohli Chief Executive Officer Tel: 609-322-1602 Email: info@gracetx.com www.gracetx.com Investor Relations: LifeSci Advisors Mike Moyer Managing Director Phone: 617-308-4306 Email: mmoyer@lifesciadvisors.com GRACE THERAPEUTICS, INC.Condensed Consolidated Balance Sheets(Unaudited) June 30, 2026 March 31, 2026 (Expressed in thousands except share data) $ $ Assets Current assets: Cash and cash equivalents 13,756 16,977 Receivables 20 20 Prepaid expenses 557 383 Total current assets 14,333 17,380 Equipment, net 7 8 Intangible assets 27,595 41,128 Goodwill 8,138 8,138 Total assets 50,073 66,654 Liabilities and Stockholders’ equity Current liabilities: Trade and other payables 1,250 2,146 Total current liabilities 1,250 2,146 Deferred tax liability 612 612 Total liabilities 1,862 2,758 Commitments and contingencies Stockholders’ equity: Preferred stock, $0.0001 par value per share; 10,000,000 authorized; none issued and outstanding as of June 30, 2026 and March 31, 2026 — — Common stock, $0.0001 par value per share; 100,000,000 authorized; 16,274,026 and 16,024,026 shares issued and outstanding as of June 30, 2026 and March 31, 2026, respectively 1 1 Additional paid-in capital 298,518 298,413 Accumulated other comprehensive loss (6,038) (6,038)Accumulated deficit (244,270) (228,480)Total stockholders’ equity 48,211 63,896 Total liabilities and stockholders’ equity 50,073 66,654 GRACE THERAPEUTICS, INC.Condensed Consolidated Statements of Loss and Comprehensive Loss(Unaudited) Three months ended June 30, 2026 June 30, 2025 (Expressed in thousands, except share and per share data) $ $ Operating expenses Research and development expenses (697) (955)General and administrative expenses (1,687) (2,135)Impairment of intangible assets (13,533) — Loss from operating activities (15,917) (3,090) Foreign exchange (loss) gain (14) 10 Change in fair value of derivative warrant liabilities — (487)Interest and other income, net 141 205 Total other income (expense) , net 127 (272)Loss before income tax benefit (15,790) (3,362) Income tax benefit — — Net loss and total comprehensive loss (15,790) (3,362) Basic and diluted loss per share (0.91) (0.21) Weighted-average number of shares outstanding 17,269,986 15,924,522

一、投资摘要与核心定位 Latigo Biotherapeutics是一家处于临床阶段的生物制药企业，专注于开发靶向电压门控钠通道Nav1.8的非阿片类口服及静脉镇痛药物。公司核心逻辑建立在阿片类药物公共卫生危机的持续深化与疼痛治疗领域巨大的未满足临床需求之上，其 lead product LTG-001已在腹壁整形术后急性疼痛的Phase 2/3试验中展现出相较于阿片类对照药Vicodin更优的镇痛幅度与更快起效速度，并计划以该试验作为支持NDA的两项关键有效性试验之一。公司已于2026年7月17日向美国SEC提交S-1注册文件，拟在纳斯达克全球精选市场上市，股票代码LTGO，由Goldman Sachs、Jefferies、Leerink Partners及Guggenheim Securities联合承销。 然而，Latigo目前仍处于高风险的临床开发早期阶段，无商业化产品、无营业收入，且面临严峻的流动性压力。截至2026年3月31日，公司累计赤字高达2.661亿美元，现金及现金等价物仅4218万美元，审计报告已包含持续经营重大疑虑的说明段落。本次IPO募资的净额，连同现有资金，预计将仅够支撑至LTG-001的Phase 3拇囊炎切除术及开放标签安全性试验的topline结果以及NDA提交准备，以及LTG-321的Phase 2骨关节炎概念验证。因此，对Latigo的投资本质上是一场基于Nav1.8机制差异化优势与临床执行能力的高杠杆押注。 二、公司沿革与资本结构 Latigo于2018年11月在特拉华州注册成立，总部位于加利福尼亚州Thousand Oaks。自成立以来，公司累计从机构投资者处募集约3.215亿美元，投资方包括Westlake BioPartners、Foresite Capital、5AM Ventures及Blue Owl Healthcare Opportunities等生命科学领域的知名机构。 在股权结构方面，招股书披露，在本次发行完成时，公司所有优先股将按现有公司章程自动转换为合计264,397,128股普通股。此外，公司于2026年6月发行了本金总额3500万美元的可转换票据，该等票据将在本次发行交割时自动转换为普通股。截至2026年3月31日，公司2019年股票计划下尚有63,299,052份股票期权流通在外，加权平均行权价为0.55美元/股。本次发行还将触发2026年股权激励计划及员工股票购买计划的生效。值得注意的是，公司作为“新兴成长公司”及“小型报告公司”，在IPO后可享受若干披露义务的减免，包括仅需提供两年经审计财务报表、豁免萨班斯-奥克斯利法案404(b)条的内部控制审计要求等，这在一定程度上降低了合规成本，但也意味着投资者可获得的历史财务与治理信息相对有限。 三、主营业务与行业赛道：非阿片类镇痛的结构性机会 疼痛治疗是美国最大、最普遍的药物治疗市场之一，每年驱动约2.5亿张处方。然而，现有治疗手段存在显著的疗效、安全性与成瘾风险之间的艰难权衡。非甾体抗炎药（NSAIDs）疗效有限，而阿片类药物虽镇痛效果强，却伴随严重的成瘾、过量使用及胃肠道不良反应，并引发了持续的社会经济危机。在此背景下，Nav1.8作为主要表达于外周神经组织、不表达于中枢神经系统的电压门控钠通道，成为非成瘾性镇痛药物开发的关键靶点。2025年1月，FDA批准了首个Nav1.8抑制剂suzetrigine（商品名Journavx，Vertex制药开发），为该治疗类别确立了明确的开发与监管先例，验证了Nav1.8机制的成药性。 Latigo的主营业务正是围绕Nav1.8抑制剂构建差异化的产品组合，覆盖急性与慢性疼痛领域。公司的初始开发重点聚焦于肌肉骨骼疼痛，其中急性术后疼痛与慢性骨关节炎疼痛患者基数庞大。公司管理层认为，凭借在疼痛生物学、临床转化及试验执行方面的深厚专长，Latigo有望构建业内最广泛的非阿片类镇痛管线之一。 四、核心产品管线深度解析 Latigo的管线以三代Nav1.8抑制剂为核心，并辅以早期离子通道调节剂发现项目，形成从急性到慢性、从口服到多种给药途径的立体布局。 （一）LTG-001：急性疼痛的潜在重磅产品 LTG-001是公司最先进的候选药物，为一种口服、选择性、强效的Nav1.8小分子抑制剂，拟用于治疗中重度急性疼痛（包括术后疼痛），按需使用最长30天，同时开发静脉注射剂型以支持住院患者从术后到出院的过渡。LTG-001的开发策略直接对标FDA对急性疼痛适应症批准的典型要求：通常需在至少一种软组织手术模型和一种硬组织（骨性）手术模型中证明重复给药方案在至少24小时内的疗效。Vertex的Journavx正是通过腹壁整形术（软组织）和拇囊炎切除术（硬组织）两项关键试验获批，Latigo亦遵循此路径。 在已完成的腹壁整形术随机、双盲、安慰剂及阳性对照试验中，LTG-001展现出极具竞争力的临床数据：高剂量组（450mg负荷剂量后每12小时300mg）的主要终点——0至48小时疼痛强度差值总和（SPID48）相较于安慰剂改善了62.1分（p<0.001），不仅具有高度统计学显著性，且在数值上超过了阿片类活性对照药氢可酮/对乙酰氨基酚（HB/APAP，即Vicodin）的40.9分改善幅度，镇痛效应高出约50%。在起效速度方面，高剂量LTG-001达到NPRS评分降低≥2分的中位时间为52分钟，显著快于Vicodin的83分钟。更具临床意义的是，高剂量组中52.3%的患者在48小时治疗期内完全未使用阿片类救援药（p<0.001），而安慰剂组仅为22.1%。低剂量组（300mg负荷后每12小时150mg）亦显示出统计学显著疗效（SPID48 37.8，p=0.003），与Vicodin效果大致相当，呈现出清晰的剂量-效应关系。 基于与FDA的沟通，公司认为该腹壁整形术试验可作为支持LTG-001用于治疗中重度急性疼痛（包括术后疼痛）的两项关键充分且良好对照试验之一。公司计划于2026年下半年启动拇囊炎切除术的安慰剂对照Phase 3试验及一项开放标签Phase 3安全性试验，预计2027年下半年获得topline结果。若结果积极，公司预计将提交NDA。此外，LTG-001已获得FDA快速通道资格（Fast Track Designation），但需注意的是，该资格并不保证更快的审评或更高的获批概率。 （二）LTG-321：慢性疼痛的接力候选 LTG-321为下一代口服Nav1.8抑制剂，与LTG-001结构不同，在临床前研究中显示出更高的活性，可能支持更低的有效剂量及每日一次给药，这对于慢性用药场景至关重要。在已完成的Phase 1试验中，截至2026年5月15日的数据显示，LTG-321在冷加压试验（CPT）中显著提高了疼痛耐受阈值，且单次给药后24小时仍保持活性。公司已于2026年启动了一项针对膝骨关节炎（OA）患者的随机、双盲、安慰剂对照、受试者内交叉设计的Phase 2概念验证试验，约入组120名患者，以WOMAC疼痛评分作为主要终点，预计2026年下半年报告topline结果。 （三）LTG-418与早期管线 LTG-418为更下一代的Nav1.8抑制剂，结构区别于前两者，预计剂量将显著低于LTG-001和LTG-321，从而可能支持凝胶、贴剂、滴眼液、吸入剂及注射剂等多种剂型，拓展疼痛市场的覆盖范围。该候选药物已完成14天非GLP毒理学研究，显示出良好的耐受性。此外，公司还在早期发现阶段探索其他参与外周疼痛传导的离子通道调节剂，作为Nav1.8抑制的补充机制，用于神经病理性疼痛等适应症。 五、临床数据质量与监管路径评估 LTG-001的腹壁整形术试验数据在统计学显著性和临床相关性上均表现优异，尤其是相较于阿片类对照药的优效性趋势和超过半数患者实现“无阿片”治疗的终点，为其潜在的标签差异化奠定了基础。目前仅有三种局部麻醉药（Exparel、Xaracoll和Zynrelef）在标签中拥有“无阿片”声明，且这些试验均允许使用阿片类作为救援药。LTG-001若能在标签中纳入无阿片声明，将成为首个拥有此标签的全身性镇痛药，具有重大的商业定位价值。 然而，监管路径仍存在不确定性。首先，尽管公司认为腹壁整形术试验可作为两项关键试验之一，但FDA最终是否接受该试验作为充分且良好对照的疗效试验，仍需视Phase 3拇囊炎试验及开放标签安全性试验的结果而定。其次，公司曾在2024年5月至11月因非临床数据不足被FDA对LTG-001的IND实施临床搁置，虽然该问题已解决，但反映出公司在非临床到临床转化过程中的执行风险。此外，LTG-001的牙科术后急性疼痛早期试验未能显示出活性治疗组与安慰剂组的统计学显著差异，而该结果未在腹壁整形术试验中重现，提示不同急性疼痛模型间的结果外推存在风险，这也为后续Phase 3试验的稳健性敲响警钟。 六、竞争格局与市场空间的现实审视 Latigo所处的非阿片类镇痛赛道竞争日益激烈。在Nav1.8靶点内，Vertex Pharmaceuticals的Journavx已率先上市，占据了明显的先发优势、监管路径验证优势和商业化资源优势。然而，Journavx的定价约为31美元/天，且部分第三方支付方已基于成本考量拒绝或限制其覆盖，这为整个Nav1.8抑制剂类别设定了不利的报销先例。Latigo若不能证明LTG-001在疗效、起效速度或安全性方面具有压倒性优势，将可能面临与Journavx相似的支付壁垒。 在研竞争者中，Eli Lilly通过2025年5月收购SiteOne Therapeutics获得了Nav1.8资产，Grünenthal GmbH及Merck Sharp & Dohme亦拥有处于不同阶段的Nav1.8候选药物。此外，其他机制的药物也在争夺疼痛市场，包括Nav1.7抑制剂（如Xenon Pharmaceuticals的XEN1701）、Kv7钾通道激活剂（如Biohaven的BHV-7000）等。在现有治疗中，阿片类药物（吗啡、羟考酮、Vicodin、曲马多）、NSAIDs（布洛芬、塞来昔布等）及局部麻醉药构成了根深蒂固的标准治疗。更值得关注的是，GLP-1受体激动剂在体重管理中的广泛应用可能间接减少某些疼痛适应症（如肌肉骨骼和炎症性疼痛）的患者基数，从而压缩疼痛药物的市场空间。 从市场机会看，急性肌肉骨骼疼痛每年影响约8000万美国成年人，慢性骨关节炎和慢性下背痛影响超过6000万人，外周神经病理性疼痛处方患者约1000万。若Latigo能够成功推出LTG-001和LTG-321，理论上可触及庞大的患者群体。但考虑到支付方日益严格的成本控制、仿制药的价格压力以及Journavx已建立的市场预期，Latigo的实际可及市场（TAM）可能显著小于理论估算。 七、核心技术平台与知识产权布局 Latigo的技术差异化不仅体现在化学结构上，更在于其临床前与临床开发工具的独特整合。公司开发了人背根神经节（DRG）神经元电生理学平台及非人灵长类微神经图（microneurography）技术，用于直接测量化合物对疼痛靶点的结合效应。在临床转化层面，公司优化了冷加压试验（CPT）作为可靠的生物标志物，能够在人体中快速、可重复地评估镇痛效果，且该终点已在LTG-001的临床结果中得到验证。这种“预临床-生物标志物-临床”的垂直整合能力，是公司管理层认为能够加速候选药物筛选与概念验证的关键。 在知识产权方面，公司依赖专利、商业秘密及与第三方签订的许可协议的组合保护其技术与候选药物。其中，与Lieber Institute for Brain Development签订的许可协议对公司业务至关重要，该协议授予了公司开发Nav1.8抑制剂相关的重要知识产权权利。然而，该协议也对公司施加了开发、监管及商业勤勉义务、里程碑付款及 royalty 义务。公司坦言，其在部分许可专利的申请、维护及执行方面并不拥有完全控制权，Lieber Institute保留在特定领域使用相关技术的权利。此外，生物制药领域的专利环境高度复杂且充满诉讼风险，公司面临第三方专利挑战、专利范围不足或无法阻止竞争对手开发类似产品的风险。截至招股书日期，公司尚未在美国境外申请任何商标的国际注册，也未获得任何药品名称的监管批准，品牌保护尚处于早期阶段。 八、管理团队与人力资本 Latigo的管理层在疼痛药物开发与商业化方面具有显著的行业深度。首席执行官Nima Farzan此前曾担任Kinnate Biopharma和PaxVax的首席执行官，在临床开发、商业化、资本募集及战略交易方面拥有丰富经验。首席医学官Neil Singla, M.D.是疼痛医学领域的资深专家，其团队已主导超过250项疼痛研究（包括50多项慢性疼痛研究），参与了超过75次FDA麻醉、成瘾医学与疼痛部门会议及14次FDA咨询委员会会议，并开创了多项增强疼痛管理研究严谨性与临床结局的专有方法学。这种在疼痛临床试验设计上的深厚积累，是Latigo能够在Journavx已验证的 regulatory path 上进一步优化试验执行的重要人力资本。 然而，作为一家仅有59名全职员工的精简型临床阶段公司，Latigo对关键管理人员及科学人员的依赖度极高。公司未为其高管购买关键人员人寿保险，且与高管签订的雇佣协议均为任意终止性质。在从临床阶段向商业化阶段过渡的过程中，公司需要在监管、制造、销售及市场等领域大幅扩充团队，其能否在激烈的人才竞争中吸引并留住足够的合格人员，存在重大不确定性。 九、财务状况与持续经营能力 Latigo的财务报表呈现出典型的临床阶段生物制药企业特征：巨额亏损、现金快速消耗、无营业收入、依赖外部融资维持运营。 在损益方面，2024年度公司净亏损约6120万美元，2025年度扩大至约1.092亿美元。2026年第一季度，净亏损为约2296万美元（去年同期为2095万美元），亏损呈持续扩大趋势，主要源于研发及临床试验活动的增加。2025年度研发费用高达9953万美元，一般及行政费用为1086万美元；2026年第一季度研发费用为1763万美元，一般及行政费用为580万美元。 在资产负债方面，截至2026年3月31日，公司现金及现金等价物为4218万美元，受限现金19.2万美元，总资产5058万美元，总负债1458万美元，累计赤字2.661亿美元，股东权益为赤字2.526亿美元。经模拟调整（包括优先股转换、可转换票据转换及本次发行募资）后，股东权益将转为正值，但具体金额取决于发行定价。公司披露，截至2026年6月30日的初步未经审计现金约为5480万美元。 尤为严峻的是，公司审计师PricewaterhouseCoopers LLP在2025年度财务报表中出具了包含持续经营重大疑虑说明段的无保留意见。公司管理层亦承认，基于当前运营计划，现有现金加上本次发行预计净额，将仅够支撑至特定里程碑节点，之后仍需大量额外融资。若无法及时获得额外资本，公司可能被迫延迟、限制或终止产品开发。这种“烧钱”速度与融资需求的紧迫性，构成了投资Latigo最核心的财务风险。 十、供应链、制造与外部依赖风险 Latigo采用典型的“轻资产”虚拟制药模式，不拥有任何药品制造设施，完全依赖第三方合同开发制造组织（CDMO）及供应商。公司的起始物料供应商位于中国，活性药物成分（API）供应商位于印度。这种高度依赖国际供应链的布局，在当前全球贸易政策动荡的背景下构成了显著风险。 招股书明确警示，美国近期通过的BIOSECURE Act（生物安全法案）可能限制联邦机构与特定中国生物技术公司的采购及合同关系，尽管现有合同有五年 grandfathering 期，且对Medicare/Medicaid供应有豁免，但未来供应链的稳定性仍存疑。此外，美国对中国及印度进口商品加征的关税，将直接增加公司的研发与生产成本，并可能因供应链调整困难而导致临床开发延迟。公司正在调查中国以外的替代供应商，但替代来源的质量、规格匹配及成本均存在不确定性。 在临床试验执行方面，公司依赖合同研究组织（CRO）及临床研究机构。公司近期正在转换CRO合作伙伴，而急性疼痛试验的入组窗口通常以周计，任何CRO过渡导致的延迟都可能对研究时间表产生不成比例的影响。此外，公司的部分Phase 1试验在新西兰完成，FDA是否完全接受境外临床数据支持美国上市申请，亦存在监管不确定性。 十一、系统性风险因素评估 除上述临床、财务及供应链风险外，Latigo还面临多维度的系统性风险： 内部控制缺陷：在编制2024及2025年度财务报表时，公司识别出一项财务报告内部控制重大缺陷，具体表现为期末财务报告流程中职责分离不足，特定人员兼具编制与审核手工日记账及账户调节表的权限。虽然该缺陷未导致财务报表错报，但若未能及时整改，可能影响未来财务信息的准确性与及时性。 网络安全事件：2026年2月，公司发生了一起商业邮件泄露（business email compromise）事件，虽经第三方安全供应商快速处置且未识别出重大损失，但反映出公司在信息安全防护方面的脆弱性。随着AI技术的使用增加，数据隐私与网络安全合规成本将持续上升。 支付方与定价压力：即使LTG-001获批，其商业化成功仍取决于能否获得有利的医保覆盖与报销。Journavx的商业化经验表明，非阿片类镇痛药面临支付方基于成本效益的严格审视。美国联邦及州层面的药品定价改革（如Medicare药品价格谈判、最惠国定价等）可能进一步压缩创新药的定价空间与盈利能力。 股东结构与流动性风险：IPO后，公司现有股东（包括高管、董事及持股5%以上的股东）将合计控制约%的流通股，具有对公司重大事项的控制或重大影响力。此外，大量股份在锁定期（180天）结束后可能涌入二级市场，对股价形成下行压力。 十二、结论与投资价值研判 Latigo Biotherapeutics代表了一种高赔率、高风险的生物技术投资范式。其价值核心在于LTG-001在急性疼痛领域已初步验证的临床优效性数据——尤其是在镇痛幅度和起效速度上相较于标准阿片类治疗的潜在优势，以及“无阿片”标签的差异化商业定位。若Phase 3拇囊炎试验及安全性试验能够复制腹壁整形术的结果，LTG-001有望在2028年左右获批上市，切入数十亿美元规模的急性术后疼痛市场。LTG-321在慢性疼痛领域的布局则为公司提供了更长期的增长期权。 然而，公司当前阶段的脆弱性同样不容忽视：极度紧张的现金状况、持续经营疑虑、对单一靶点（Nav1.8）和少数候选产品的高度依赖、激烈的同类竞争（尤其是已上市的Journavx）、复杂的国际供应链风险以及尚未验证的商业化能力，均意味着Latigo在达到盈亏平衡点前仍需跨越多重生死关卡。本次IPO募资虽能解燃眉之急，但距离LTG-001的NDA提交及潜在商业化仍有巨大资金缺口。 对于投资者而言，Latigo的吸引力在于其可能成为Nav1.8赛道中“比Journavx更好”的第二代产品，但前提是公司必须在接下来的18个月内 flawless 地执行两项Phase 3试验、解决供应链与制造瓶颈、并构建起足以应对支付方壁垒的商业化策略。在现有财务条件下，任何临床延迟、监管挫折或融资环境恶化，都可能导致公司面临急剧的价值重估下行风险。因此，Latigo更适合对临床阶段生物制药风险有充分认知、且能够承受本金全部损失的专业投资者。其长期价值实现的关键变量，将集中在2027年下半年LTG-001的Phase 3数据读出与2028年前后潜在的NDA审评结果。